Eli Lilly ·
Eli Lilly executives have provided congressional testimony on compounded tirzepatide issues, most notably before the House Energy and Commerce Subcommittee on Health in May 2025 and the Senate HELP Committee in February 2026. Lilly's testimony has emphasized patient safety concerns regarding unregulated compounded products, the company's direct-to-consumer pricing through LillyDirect, and the importance of maintaining the integrity of the drug approval pathway. Critics — including some members of Congress and consumer advocates — have questioned Lilly's pricing strategy and whether competitive motivations drive the company's enforcement activity more than safety concerns.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.